What happened with FDMT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
4D Molecular Therapeutics is developing gene medicines, with its main late-stage effort focused on 4D-150 for wet age-related macular degeneration and diabetic macular edema, two retinal diseases that affect vision. It aims to reduce patients’ need for repeated treatments. 4D-150 is in Phase 3 clinical trials; the company has no approved products and has never generated product-sales revenue.
Pharmaceutical partners pay the company for development and commercial rights, through upfront payments, milestone payments and development-cost reimbursements. Revenue has been dominated by Otsuka Pharmaceutical’s upfront payment for exclusive rights to 4D-150 in Japan, China, Australia and other Asia-Pacific markets. Otsuka handles regulatory and commercialization work there, while 4D Molecular Therapeutics leads global Phase 3 trials and retains rights outside those markets, including the United States and Europe.
Further payments under the Otsuka agreement depend on regulatory and commercial milestones, with royalties tied to future sales. Product sales require successful clinical development and regulatory approval. The company has funded its research mainly by issuing shares, rather than through operating revenue.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
4D Molecular Therapeutics’ prospects hinge on 4D-150’s clinical success and Asia-Pacific partner Otsuka, whose agreement provides development cost sharing, potential milestones and royalties.
REGENXBIO’s sura-vec, developed with AbbVie, competes with 4D Molecular Therapeutics’ 4D-150 to bring gene therapy to patients with wet AMD and related retinal vascular disease. Watch sura-vec’s clinical progress as a competing approach to treating these patients; 4D-150 remains unapproved.
Regeneron’s EYLEA medicines already serve the retinal patients that 4D Molecular Therapeutics hopes to reach with 4D-150, its unapproved gene therapy designed to produce aflibercept and reduce treatment burden. Watch sales of EYLEA and EYLEA HD for how the established treatments that 4D-150 would need to displace are performing.
Regeneron Pharmaceuticals Inc earningsREGN
Regeneron’s EYLEA and EYLEA HD sales will show how firmly the established retinal treatments that 4D Molecular Therapeutics’ 4D-150 aims to displace are holding their market.
Look at Regeneron’s reported EYLEA and EYLEA HD sales. Steady or rising sales would show continued demand for established aflibercept treatments, leaving 4D-150 a stronger incumbent to displace even if approved. Weakening sales would point to less demand for those treatments, but would not show that patients will switch to an unapproved 4D-150.
4D Molecular Therapeutics, Inc. earningsThis company
4D Molecular Therapeutics has no approved products, so this report will show whether collaboration revenue is keeping pace with research spending and easing the cost of advancing its pipeline.
Read collaboration and license revenue alongside research and development expense and the operating loss. Rising partner revenue with slower expense growth and a narrower operating loss would show partners are covering more of the development burden. Little partner revenue with research costs still climbing and a wider operating loss would show 4D Molecular Therapeutics is still funding most of that work itself.
